» Articles » PMID: 11586110

Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms

Overview
Specialty Pharmacology
Date 2001 Oct 5
PMID 11586110
Citations 265
Authors
Affiliations
Soon will be listed here.
Abstract

Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Spinal cord injury may be divided into both primary and secondary mechanisms of injury. The primary injury, in large part, determines a given patient's neurologic grade on admission and thereby is the strongest prognostic indicator. However, secondary mechanisms of injury can exacerbate damage and limit restorative processes, and hence, contribute to overall morbidity and mortality. A burgeoning body of evidence has facilitated our understanding of these secondary mechanisms of injury that are amenable to pharmacological interventions, unlike the primary injury itself. Secondary mechanisms of injury encompass an array of perturbances and include neurogenic shock, vascular insults such as hemorrhage and ischemia-reperfusion, excitotoxicity, calcium-mediated secondary injury and fluid-electrolyte disturbances, immunologic injury, apoptosis, disturbances in mitochondrion function, and other miscellaneous processes. Comprehension of secondary mechanisms of injury serves as a basis for the development and application of targeted pharmacological strategies to confer neuroprotection and restoration while mitigating ongoing neural injury. The first article in this series will comprehensively review the pathophysiology of SCI while emphasizing those mechanisms for which pharmacologic therapy has been developed, and the second article reviews the pharmacologic interventions for SCI.

Citing Articles

Fidgetin-like 2 knockdown increases acute neuroinflammation and improves recovery in a rat model of spinal cord injury.

Smith A, Nagrabski S, Baker L, Kramer A, Sharp D, Byrnes K J Neuroinflammation. 2025; 22(1):73.

PMID: 40065364 PMC: 11895163. DOI: 10.1186/s12974-025-03344-3.


Reawakening inflammation in the chronically injured spinal cord using lipopolysaccharide induces diverse microglial states.

John R, Vogel S, Zia S, Lee K, Nguyen A, Torres-Espin A J Neuroinflammation. 2025; 22(1):56.

PMID: 40022205 PMC: 11871772. DOI: 10.1186/s12974-025-03379-6.


Critical roles of miR-21 in promotions angiogenesis: friend or foe?.

Saadh M, Jasim N, Ahmed M, Ballal S, Kumar A, Atteri S Clin Exp Med. 2025; 25(1):66.

PMID: 39998742 PMC: 11861128. DOI: 10.1007/s10238-025-01600-7.


Cross-cultural adaptation and validation of the "impact on participation and autonomy" (IPA) questionnaire in Indian population with spinal cord injury.

Kumari R, Joshi R, Vijay P Spinal Cord Ser Cases. 2025; 11(1):2.

PMID: 39833170 PMC: 11747401. DOI: 10.1038/s41394-025-00697-y.


Targeting Remyelination in Spinal Cord Injury: Insights and Emerging Therapeutic Strategies.

Al Mamun A, Quan Z, Geng P, Wang S, Shao C, Xiao J CNS Neurosci Ther. 2024; 30(12):1-15.

PMID: 39723448 PMC: 11669846. DOI: 10.1111/cns.70193.